Hold: In line 3Q17, limited market share gain in Oct 3Q slight miss; Cotai likely delayed till 2019 Strong quarter driven by both organic growth and acquired assets Buy: Solid earnings growth momentum Buy: 9M17 results within expectations 3Q results core earnings up by 38%;reiterate Buy 3Q17 results - decent OP numbers but investment losses; maintain Buy Consensus low; undemanding valuation; Buy re-iterated 3Q17: A solid top-line eroded by higher costs and D&A The war on entecavir, TDF and TAF